Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 8/20 | 0.42 |
| ▸ | VRK1 | Q99986 | 5/20 | 0.40 |
| ▸ | VRK2 | Q86Y07 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.40 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.40 |
| ▸ | STK4 | Q13043 | 4/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080835 | 0.82 | PIP4K2A (0.39) | RPS6KA3STK4PIP4K2APIP4K2BPLK1 | |
| SCHEMBL4089766 | 0.82 | VRK1 (0.39) | RPS6KA3VRK1STK4PIP4K2APIP4K2B | |
| SCHEMBL4089875 | 0.81 | VRK1 (0.41) | VRK1BRD4PLK1 | |
| SCHEMBL3543954 | 0.80 | RPS6KA3 (0.45) | RPS6KA3VRK1VRK2JAK2BRD4 | |
| SCHEMBL4085053 | 0.78 | RPS6KA3 (0.41) | RPS6KA3SMN1; SMN2 | |
| SCHEMBL1203549 | 0.75 | PIP4K2A (0.38) | BRD4PIP4K2APIP4K2BPLK1PLK2 | |
| SCHEMBL4082908 | 0.75 | PIP4K2A (0.36) | BRD4STK4PIP4K2APIP4K2BPLK1 | |
| SCHEMBL3668145 | 0.74 | PIP4K2A (0.38) | BRD4PIP4K2APIP4K2BPLK1PLK2 | |
| SCHEMBL4079498 | 0.74 | MAPT (0.39) | RPS6KA3VRK1BRD4STK4SMN1; SMN2 | |
| SCHEMBL21261610 | 0.74 | STK4 (0.50) | RPS6KA3VRK1VRK2JAK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | RPS6KA3 771/4885VRK1 1326/4885VRK2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.